Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026
Company Drug

Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market

Fineline Cube Mar 18, 2024

Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide)...

Company Drug

FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma

Fineline Cube Mar 18, 2024

An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...

Company Drug

Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR

Fineline Cube Mar 15, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...

Company Deals

AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline

Fineline Cube Mar 15, 2024

AstraZeneca (AZ; NASDAQ: AZN) has finalized a definitive agreement to acquire France-based biopharmaceutical company Amolyt...

Company Drug

KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma

Fineline Cube Mar 15, 2024

Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...

Company Deals

Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy

Fineline Cube Mar 15, 2024

Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...

Company Drug

Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma

Fineline Cube Mar 15, 2024

Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...

Company Drug

Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults

Fineline Cube Mar 15, 2024

The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’...

Deals Hospital

Swire Pacific to Deepen Healthcare Investment Focus in China and Indonesia

Fineline Cube Mar 15, 2024

Swire Pacific, a Hong Kong-based conglomerate, is gearing up to focus on healthcare investments in...

Legal / IP

CNIPA Invalidates Novo Nordisk’s Victoza Patent, Opening Door for Chinese Biosimilars

Fineline Cube Mar 14, 2024

The China National Intellectual Property Administration (CNIPA) has declared invalid the patent No. 201510572124.1 held...

Drug Legal / IP

CNIPA Invalidates AbbVie Patents, Setting New Precedent for Pharmaceutical Disclosure

Fineline Cube Mar 14, 2024

The China National Intellectual Property Administration (CNIPA)’s Patent Re-examination Board (PRB) has reportedly invalidated two...

Company

BeiGene Launches Charitable Access Program for Brukinsa in Low-Income Countries

Fineline Cube Mar 14, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has announced that...

Company

Innovent Biologics Denies Lab Closure, Confirms Relocation to California

Fineline Cube Mar 14, 2024

Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland...

Company Deals

Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline

Fineline Cube Mar 14, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...

Company Legal / IP Policy / Regulatory

BIO Reverses Support for WuXi AppTec Amid Security Concerns, Plans Legislative Shift

Fineline Cube Mar 14, 2024

The Biotech Innovation Organization (BIO), a US-based industry lobbying group, has reversed its stance on...

Company Drug

European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use

Fineline Cube Mar 14, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...

Company Drug

Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations

Fineline Cube Mar 14, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human...

Company Deals

Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development

Fineline Cube Mar 14, 2024

Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a...

Company Drug

Allist Pharmaceuticals Secures NMPA Approval for Phase I Study of AST2169 Liposome in KRAS G12D Tumors

Fineline Cube Mar 14, 2024

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) has received clearance from the National Medical...

Company Deals

BioGeometry and Sanyou Biopharmaceuticals Forge AI Partnership for Antibody Drug Discovery

Fineline Cube Mar 14, 2024

BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou...

Posts pagination

1 … 340 341 342 … 617

Recent updates

  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
  • CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.